Medicinal Cannabis Products, Made in New Zealand
Cannasouth was New Zealand’s first medicinal cannabis company to list on the New Zealand Stock Exchange (NZX:CBD) in June 2019. We are a vertically integrated biopharmaceutical company dedicated to advanced medicinal cannabis product development and research. Our goal is to develop next-generation medicinal cannabis products for prescribers and patients in New Zealand and export these pharmaceutical quality products and technologies globally.
We will produce our cannabis-based medicines and ingredients using cannabinoid extracts from high-quality, medical-grade cannabis cultivars. These medicines will be manufactured under GACP and GMP regulations using environmentally friendly methods, ensuring patients are treated with sophisticated medicines made of pure therapeutic compounds of the highest quality.
Cannasouth announces opening of a $6 million offer to retail investors
Open 16 – 30 July 2021
Further information is available on our investor centre home page.
For full details on the capital raise strategy and structure of the offer, visit http://www.cannasouthshareoffer.com
A copy of the Cleansing Notice, the Retail Offer Announcement, the Corporate Action Notice, the SPP Offer Document and the General Retail Offer Document can be found at https://www.nzx.com/companies/CBD/announcements
Cannasouth provides medicinal cannabis clinical data, educational material and media for specialists, doctors, and clinicians enabling informed patient treatment choices.
Supporting patient access to high-quality educational material regarding cannabinoid therapeutics is central to meaningful health outcomes.
Our investors are critical to the success of the company. We acknowledge the special trust they place in us with our commitment to the expansion of Cannasouth.